FemPulse is one of only ten companies from around the world selected to present at the International Neuromodulation Society (INS) “Innovations in Neuromodulation” panel on June 6, 2015 in Montreal. This biennial event is part of INS’s 12th World Congress, featuring the most innovative neuromodulation companies.
Dr. Alexandra Haessler, founder of FemPulse, is presenting the patented FemPulse non-implanted neuromodulation platform, designed as 1st-line therapy for OAB and other indications. Dr. Haessler said: “After three years of building our strong intellectual property and developing our technology, it is a pleasure to present at INS’s biennial conference. Our cost-effective approach to serving women around the world with patient-friendly non-implanted neuromodulation fits well with the Innovation Day focus on value and global patient access.”
INS describes FemPulse as having “patented a first-line neuromodulation platform technology to treat overactive bladder and other autonomic conditions in women with a non-implanted, vaginally-inserted ring-shaped device wearable around a woman’s cervix to target autonomic nerves.”
Click here for the INS “Innovations in Neuromodulation” press release and here for the June 6 schedule.
